Stay updated on Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial

Sign up to get notified when there's something new on the Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    Revision: v3.5.0 released, replacing v3.4.3. This update updates the site version and UI without altering study details.
    Difference
    0.1%
    Check dated 2026-03-19T06:19:45.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    Revision: v3.4.3 is displayed, replacing the previous v3.4.2.
    Difference
    0.1%
    Check dated 2026-03-12T02:24:06.000Z thumbnail image
  5. Check
    51 days ago
    Change Detected
    Summary
    Revision updated to v3.4.2. Older notices including v3.4.1 and the government funding status notice were removed.
    Difference
    0.5%
    Check dated 2026-02-11T14:19:11.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    Added a general status notice about government funding and NIH operations, and updated the site software version to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2026-02-04T10:40:00.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    Added a glossary toggle and new metadata labels: 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0'. Removed the previous labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'.
    Difference
    0.2%
    Check dated 2026-01-28T06:38:16.000Z thumbnail image
  8. Check
    72 days ago
    Change Detected
    Summary
    Key sections including Interventions/Treatment, Outcome Measures, Eligibility Criteria, and Study Record Dates appear to be removed. This reduces visibility into the trial design, endpoints, and enrollment details.
    Difference
    17%
    Check dated 2026-01-21T04:25:48.000Z thumbnail image

Stay in the know with updates to Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial page.